Evidence map›Paper›PMID 41915703›Full record

SynthesisHuman reproduction update2026

The risk for the development of hypertensive complications in oocyte donation pregnancy: a systematic review and individual participant data meta-analysis (DONOR IPD).

Kim van Bentem, Marie-Louise van der Hoorn, Manish Banker, Maria de la Calle, Evangelia Elenis, Dina El Demellawy, Nathan S Fox, Yadava Jeve, Diane Korb, Hélène Letur and 10 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Human reproduction update, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kim van BentemDepartment of Gynecology and Obstetrics, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-2878-8739
Marie-Louise van der HoornDepartment of Gynecology and Obstetrics, Leiden University Medical Center, Leiden, The Netherlands.
Manish BankerBanker IVF & Women's Hospital, Ahmedabad, India.
Maria de la CalleDepartment of Obstetrics and Gynecology, La Paz Hospital, Madrid, Spain.
Evangelia ElenisDepartment of Women's and Children's Health, Uppsala University Hospital, Uppsala, Sweden.ORCID 0000-0002-2253-4682
Dina El DemellawyDepartment of Pediatric Pathology, Children's Hospital of Eastern Ontario, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Nathan S FoxDepartment of Obstetrics, Gynecology, and Reproductive Science, Mount Sinai School of Medicine, New York, NY, USA.
Yadava JeveBirmingham Women's and Children's Hospital, Birmingham, United Kingdom.ORCID 0000-0002-5389-9588
Diane KorbDepartment of Obstetrics and Gynecology, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.ORCID 0000-0002-3074-8269
Hélène LeturDepartment of Obstetrics and Gynecology, Reproductive Medicine and Fertility Preservation, Foch Hospital, Suresnes, France.
Yoav YinonDepartment of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Antonio FarinaObstetric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Francesca RizzelloAssisted Reproductive Technology Centre, Careggi University Hospital, Florence, Italy.
Kenny A Rodriguez-WallbergDepartment of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska University Hospital & Karolinska Institutet, Stockholm, Sweden.
Michal SimchenDepartment of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel.
Serena SimeoneDepartment of High Risk Pregnancy, Careggi University Hospital, Florence, Italy.
Theoni TarlatziFertility Clinic, Department of Obstetrics and Gynecology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Stefano Raffaele GiannubiloDepartment of Clinical Sciences, Università Politecnica delle Marche, Ancona, Italy.
Saskia Le CessieDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-2154-4923
Eileen LashleyDepartment of Gynecology and Obstetrics, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-3410-2294

Funding

Leiden University Medical CenterRadiumhemmets Research Funds and CancerfondenThe Swedish Cancer Society
6 · The paper itself

Abstract

backgroundOocyte donation (OD) is an established ART involving an oocyte donor and recipient with a rising number of treatments. Previous meta-analyses highlight increased risks of hypertensive complications compared to naturally conceived (NC) and IVF/ICSI pregnancies, including pregnancy-induced hypertension (PIH) and preeclampsia (PE), but limitations exist due to study quality and heterogeneity. OBJECTIVE AND RATIONALE: The DONOR (DONation of Oocytes in Reproduction) individual participant data (IPD) meta-analysis aims to generate clinically relevant and robust evidence regarding the development of hypertensive complications in OD pregnancies compared to autologous pregnancies. IPD meta-analyses offer an advantage over current meta-analyses, as bias is reduced by using IPD of original studies, allowing reliability checks, correction for confounders, and examining causes of heterogeneity by subgroup analyses. Furthermore, using IPD increases statistical power and generalizability of results. SEARCH

methodsA literature search was conducted using PubMed, EMBASE, and Cochrane up to March 2024, with a last update performed in February 2025. We included observational studies that compared a cohort of women pregnant after OD beyond 20 weeks of gestation with an autologous pregnancy cohort (NC or IVF/ICSI), and reported on hypertensive pregnancy complications. Risk of bias was assessed using the ROBINS-I tool. Authors of eligible articles were invited to share IPD. The DONOR IPD meta-analyses were executed using both a one- and two-stage approach, adjusted for maternal age, parity, and multiple gestation. Furthermore, sensitivity, meta-regression and subgroup analysis were performed. OUTCOMES: IPD was requested for 48 cohorts, and provided from 16 cohorts with data of 2747 OD, 4699 IVF/ICSI, and 33 323 NC pregnancies. The one- and two-stage approach comparing OD to autologous pregnancies showed adjusted ORs of respectively 2.62 (95% CI 2.22-3.10) and 2.85 (95% CI 2.30-3.54; I2 44%; moderate certainty) for hypertensive complications in total, 2.15 (95% CI 1.73-2.68) and 1.49 (95% CI 0.80-2.80; I2 74%; low certainty) for PIH, and 2.28 (95% CI 1.88-2.78) and 2.39 (95% CI 1.94-2.94; I2 0%; high certainty) for PE. When the autologous group was split into NC and IVF/ICSI pregnancies, higher risks for hypertensive complications, including PIH and PE, persisted in the OD group. The results of the IPD meta-analyses for HELLP syndrome show a higher risk in OD pregnancy, though with a broad 95% CI. Sensitivity meta-analyses for risk of bias showed comparable results. Subgroup analyses indicated increased risks for hypertensive complications in OD pregnancy, regardless of maternal age, BMI, multiple pregnancy, parity, ethnicity, medical history, and number of transferred embryos. A potential lower risk for hypertensive complications was found when acetylsalicylic acid or heparin is used during OD pregnancy compared to both autologous and NC pregnancy. WIDER IMPLICATIONS: The DONOR IPD meta-analysis provided a unique opportunity to assess the risk for hypertensive complications in OD compared to autologous pregnancy. The results must increase alertness of health care professionals who are involved in OD health care towards the risk profile of these pregnancies, as the DONOR IPD meta-analysis results in the best evidence-based statement for international guidelines in obstetrics to date. Possibly, preventive treatment with low-dose acetylsalicylic acid is successful in lowering the risk for hypertensive complications, though more evidence is needed to confirm this effect, alongside the underlying pathological mechanism. REGISTRATION NUMBER: CRD42021267908.

Indexed as

Hypertension, Pregnancy-InducedOocyte DonationFemaleHumansPre-EclampsiaPregnancyRisk Factorshypertensive pregnancy complicationsindividual participant data meta-analysisoocyte donationpreeclampsiapregnancypregnancy induced hypertension

Identifiers

PMID41915703
PMCPMC13319335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.